The pace of health care mergers and acquisitions slowed considerably in January 2016. In part, that’s due to the rush to get business off the books by the end of the calendar year, which is why fourth quarters are usually so busy. This year we’ve counted about 95 transactions announced in January, which is 32% […]
Halfway through the month of January 2016, 12 pharmaceutical deals have been announced, with a total of $32.8 billion. You might think that’s a result of the annual JP Morgan Healthcare Summit that’s held every year in the second week of January. That’s only half right. Last year, only nine pharma deals were announced the […]
With one week to go in 2015, there are still a few big pharmaceutical deals in the works. Shire plc (NASDAQ: SHPG) is now in friendly talks to take over Baxalta International Inc. (NYSE: BXLT) for a price rumored to be above $30 billion. By who’s waiting for 2016? Here is a preliminary tally of the […]
Shire plc (NASDAQ: SHPG) is on a buying binge in 2015. After agreeing to be acquired by AbbVie (NYSE: ABBV) for $54.7 billion in July 2014, the deal fell apart in October following the Treasury Department’s revised ruling on foreign domiciles. Shire management turned around and acquired rare disease drug maker NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) in […]
Last week we noted that April was a slow month for healthcare deals. Then we checked our database, DealSearchOnline.com, and discovered there have been 19 billion-dollar deal announcements already in 2015, through May 8th, with a combined total of $103.6 billion. The total for the entire year is about to top $120 billion, on 487 […]
It’s not over until the fat check arrives. That’s the story of Salix Pharmaceuticals (NASDAQ: SLXP), which last month accepted Valeant Pharmaceuticals’ (NYSE: VRX) $10.1 billion acquisition offer. Valeant thought it had snatched victory from Shire plc (NASDAQ: SHPG) and Endo International plc (NASDAQ: ENDP), which were also readying bids for the troubled Salix. Endo […]
Already in 2015, we’ve recorded 11 billion-dollar-plus deals, for a total of $64.4 billion. Thanks to the $21 billion AbbVie (NYSE: ABBV) bid for Pharmacyclics (NASDAQ: PCYC), the biotechnology sector accounted for $27.5 billion of those big deals. Pharmaceuticals, with four billion-plus transactions, still ranks first, with combined spending of $30.45 billion.